Saturday 17 October 2026 Export VBIO’s income statement to Excel — free account

Valion Bio, Inc.

Valion Bio, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $780,000.00, down 33.7% from fiscal 2023. In the quarter to June 2026, revenue grew 15.9%, EPS was flat and free cash flow fell 189.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

1.17 0.06 −4.88%

Follow VBIO

Alert me

Market cap: $2.4M
P/E: 0.0×
Fwd P/E: 0.0×
Dividend yield: —
F-score: 3/9
Altman Z: −21.96
Beneish M: 48.80
Dividend safety: n/a

Overview Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.03

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	2	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 2.39

Revenue 0.48

Net Income (18.23)

Free Cash Flow (14.67)

Net Debt 5.28

Current Ratio 1.11

Debt/Equity 0.62

P/E ratio 0.00

Fwd P/E 0.00

P/S ratio 0.33

P/B ratio 0.04

Past 5Y EPS Growth —

This Y EPS Growth —

Next Y EPS Growth —

Next Y revenue growth 929.49%

Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 0.08%

10-year low 10-year high

P/B against its own 10 years 0.08%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2020	Powerpack
2019	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	3	2	13	2
Receivables	0	0	—	—
Inventory	1	0	—	1
Other	—	—	—	—
	5	3	13	3

	2023	2024	2025	Q'26
Payables	1	0	0	1
ST’ Debt	—	—	—	—
Other	—	—	—	—
	1	0	1	3

Compound Annual Growth %

	10y	5y	3y
Sales	—	13.18%	(14.71%)
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	0.00%	88.12%

Revenue $m

	Mar	Jun	Dec	Year
’26	0	0	—	—
’24	0	0	0	1
’23	0	0	0	1
’22	0	1	0	2
’21	0	0	0	1
’20	—	—	0	1

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(5)	(5)	—	—	—
’25	(1)	(2)	(2)	(2)	(7)
’24	(2)	(1)	(1)	(1)	(6)
’23	(2)	(2)	(2)	(2)	(9)
’22	(2)	(2)	(3)	(2)	(9)
’21	(1)	(1)	(2)	(3)	(6)
’20	—	—	(1)	(3)	(3)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(5)	(5)	—	—	—
’25	(1)	(2)	(2)	(2)	(8)
’24	(2)	(1)	(1)	(1)	(6)
’23	(3)	(2)	(2)	(2)	(9)
’22	(2)	(2)	(3)	(2)	(9)
’21	(1)	(1)	(2)	(3)	(6)
’20	—	—	(1)	(3)	(3)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(55.75)	(54.25)	—	—	—
’25	(63.00)	(54.75)	(49.25)	(22.21)	(196.00)
’24	(429.42)	(136.05)	(97.79)	169.29	(492.00)
’23	(4.68k)	(2.98k)	(629.25)	3.73k	(4.42k)
’22	(9.78k)	(13.61k)	(11.48k)	(9.78k)	(44.22k)
’21	(24.70k)	(19.59k)	(38.26k)	(20.84k)	(103.38k)
’20	—	—	(0.10)	(0.12)	(67.17k)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	—	140,675.00	21,675.00	488.75	85.43	35.00	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	—	276,250.00	172,975.00	36,125.00	952.00	391.00
People
People	Employees	—	—	—	—	8	7	16	9	7	52
	Revenue/emp, $m	—	—	—	0.00	0.11	0.18	0.12	0.13	0.11	0.00
Income, $m
Income, $m	Revenue	—	—	—	0	1	1	2	1	1	—
	Gross margin, %	—	—	—	(68.81)	(26.16)	(3.02)	16.25	24.40	0.26	—
	EBT	—	—	—	(4)	(4)	(8)	(10)	(8)	(4)	(8)
	EBT margin, %	—	—	—	(987.14)	(423.14)	(675.74)	(548.70)	(701.02)	(573.08)	0.00
	Net income	—	0	—	(4)	(4)	(8)	(10)	(8)	(4)	(8)
	Depreciation	—	—	—	0	0	2	0	0	0	0
Per share, $
Per share, $	Revenue	—	—	—	4,200.00	8,600.00	12,570.00	9,200.00	618.95	67.83	0.00
	Earnings	—	—	—	(76,678.50)	(67,174.77)	(103,381.60)	(44,217.70)	(4,421.77)	(492.00)	(196.00)
	Cash flow	—	—	—	(36,700.00)	(30,270.00)	(56,120.00)	(44,595.00)	(4,479.47)	(497.83)	(151.49)
	Capex	—	—	—	(310.00)	0.00	0.00	(55.00)	(62.11)	0.00	(12.58)
	Free cash flow	—	—	—	(37,010.00)	(30,270.00)	(56,120.00)	(44,650.00)	(4,541.58)	(497.83)	(164.07)
	Book value	—	—	—	23,710.00	(11,770.00)	132,720.00	18,150.00	1,884.21	220.43	523.10
	Shares, m	—	—	—	0	0	0	0	0	0	0
Valuation, ×
Valuation, ×	P/E	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00	—
	P/S	—	—	—	17.80	17.80	13.12	3.03	1.24	2.17	—
	P/B	—	—	—	0.00	0.00	1.24	1.53	0.41	0.67	—
	EV/Sales	—	—	—	18.88	18.88	3.23	1.31	(1.44)	(0.09)	—
	EV/FCF	—	—	—	(3.98)	(3.98)	(0.72)	(0.27)	0.20	0.01	—
Cash, $m
Cash, $m	Operating cash flow	—	—	—	(4)	(3)	(6)	(9)	(9)	(6)	(7)
	Capex	—	—	—	0	—	—	0	0	—	(1)
	Free cash flow	—	—	—	(4)	(3)	(6)	(9)	(9)	(6)	(8)
Balance, $m
Balance, $m	Working capital	—	—	—	2	0	13	3	3	2	12
	Total debt	—	—	—	—	1	1	0	—	—	6
	Net debt	—	—	—	(2)	0	(12)	(3)	(3)	(2)	(6)
	Shareholders’ equity	—	—	—	2	(1)	13	4	4	3	24
Returns, %
Returns, %	ROA	—	—	—	(274.34)	(159.78)	(102.54)	(96.56)	(149.46)	(142.01)	(52.63)
	ROIC	—	—	—	(3,794.79)	0.00	(418.13)	(1,314.84)	(2,785.47)	(524.86)	(27.46)
	ROE	—	—	—	(695.97)	(610.57)	(140.47)	(119.47)	(228.68)	(184.96)	(93.69)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2024 · latest quarter Sep 2025

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
EIGRQ Eiger BioPharmaceuticals, Inc.	$2.6M	— (loss-making)	— (loss-making)	+41.06% (above 0%: growing)	n/m	+37.90% (above 0%: growing)	97.34%	(331.69%)	Compare
BIORQ Biora Therapeutics, Inc.	$2.5M	— (loss-making)	— (loss-making)	+1,500.00% (above 0%: growing)	n/m	+20.72% (above 0%: growing)	100.00%	(50,709.38%)	Compare
ELAB PMGC Holdings Inc.	$2.5M	— (loss-making)	—	+147.70% (above 0%: growing)	n/m	−44.95% (below 0%: shrinking)	29.52%	(292.91%)	Compare
VBIO Valion Bio, Inc.	$2.4M	— (loss-making)	— (loss-making)	+15.87% (above 0%: growing)	n/m	−189.01% (below 0%: shrinking)	(99.32%)	0.00%
NTBLQ Notable Labs, Ltd.	$2.4M	— (loss-making)	— (loss-making)	−96.88% (below 0%: shrinking)	n/m	−26.63% (below 0%: shrinking)	100.00%	(269,000.00%)	Compare
MTNB Matinas Biopharma Holdings, Inc.	$2.4M	— (loss-making)	— (loss-making)	+365,433.33% (above 0%: growing)	n/m	+9.15% (above 0%: growing)	0.00%	0.00%	Compare
BPTSY Biophytis SA Sponsored ADR	$2.4M	— (loss-making)	—	—	n/m	+53.15% (above 0%: growing)	0.00%	—	Compare
WINT Windtree Therapeutics, Inc.	$2.4M	— (loss-making)	— (loss-making)	−100.00% (below 0%: shrinking)	n/m	+1.12% (above 0%: growing)	0.00%	0.00%	Compare
KAPA Kairos Pharma, Ltd.	$2.3M	— (loss-making)	—	—	n/m	−25.71% (below 0%: shrinking)	—	0.00%	Compare
Median of peers	$2.4M	—	—	+94.38%	—	+5.14%	29.52%	(292.91%)

All 614 Biotechnology stocks →

Valion Bio, Inc. (VBIO) key facts

Concern: Valion Bio, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $780,000.00, down 33.7% from fiscal 2023.
Valion Bio, Inc. (VBIO) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, VBIO traded at $1.17, a market capitalization of $2.4 million.
Return on equity was −93.7% and debt-to-equity 0.62.
Its Piotroski F-score is 3 out of 9 and its Altman Z-score is −21.96 (distress zone) for fiscal 2024.

Source: company filings (standardised) and stockrow calculations.